Among patients with FGFR2amp cancers, GC and GEJ cancers were observed to have a higher percentage of high (+++) FGFR2 amplifications (39.5% [104/263] and 27% [71/263] for GC and GEJ cancers, respectively; Figure 2; Supplementary Figure S1). This evidence concerns the gene FGFR2 and cancer.